Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

OBJECTIVE: To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3–4) enrolled in clinical trials. RESEARCH DESIGN AND METHODS: This analysis pooled data from 19 randomized, placebo-controlled, phase 1–4 clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuttle, Katherine R., Levin, Adeera, Nangaku, Masaomi, Kadowaki, Takashi, Agarwal, Rajiv, Hauske, Sibylle J., Elsäßer, Amelie, Ritter, Ivana, Steubl, Dominik, Wanner, Christoph, Wheeler, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210861/
https://www.ncbi.nlm.nih.gov/pubmed/35472672
http://dx.doi.org/10.2337/dc21-2034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210861/
https://www.ncbi.nlm.nih.gov/pubmed/35472672
http://dx.doi.org/10.2337/dc21-2034

Ejemplares similares